- AGC Biologics has partnered with ATUM to integrate the Leap-In Transposase expression platform into its Cell Line Development Centre of Excellence.
- The collaboration is intended to increase yields, shorten development timelines and expand CDMO service options for drug developers.
AGC Biologics has expanded its Cell Line Development Centre of Excellence through a partnership with ATUM, integrating the Leap-In Transposase expression platform into its global CDMO offering. The collaboration aims to support drug developers under pressure to reduce costs and accelerate time to market by providing technology designed to increase yields and shorten the path to clinical trials.
According to the announcement, the Leap-In platform will become part of a suite of cell line development options covering both complex molecules requiring rapid development and projects with less time-sensitive requirements. ATUM’s technology is based on a transposase system that stably integrates DNA into a host cell’s genome, enabling faster generation of productive and genetically stable lines. The platform can reduce timelines by an average of three months, with stable pools offering predictive insight into final clonal line performance.
AGC Biologics stated that the collaboration brings additional cell engineering expertise to support next-generation antibody programmes, including those targeting cancer, viral infections and autoimmune disorders. The company said the integration of ATUM’s platform with its existing miCHO and CHEF1 technologies will expand flexibility for customers seeking customised solutions aligned with molecule complexity, budget and timelines.
“Our partnership with ATUM is a direct response to that need. We are not just adding a new technology; we are providing our customers with more options and flexibility.” He added that the plan is to integrate and optimise the Leap-In and miCHO technologies.
Kasper Møller, Chief Technical Officer at AGC Biologics
ATUM’s Co-Founder Claes Gustafsson said the platform was designed to improve expression robustness, maximise efficiency and increase speed to clinic. The combined offering will be available across AGC Biologics’ sites in the United States, Europe and Asia.
